Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment

Author(s):  Meissner Svenja, Bansal Mahima, Dela Cruz Paula Donamae, Hanning Sara, Svirskis Darren

Issue:  Mar/Apr 2020 - Volume 24, Number 2
View All Articles in Issue

Page(s):  140-147

The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment Page 1
The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment Page 2
The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment Page 3
The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment Page 4
The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment Page 5
The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment Page 6
The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment Page 7
The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment Page 8

Download in electronic PDF format for $75

Abstract:  In New Zealand, there are no liquid formulations of omeprazole commercially available, therefore suspensions must be extemporaneously compounded from solid dosage forms for patients with swallowing difficulties. The funding for solid dosage forms of omeprazole changes frequently, often every one to two years, without consideration of the impact this may have when extemporaneously compounded liquid dosage forms are required. This study examined suspensions compounded from various solid dosage forms of omeprazole with the purpose of identifying suitable quality formulations and evaluating their chemical and physical stability. Six different solid dosage forms of omeprazole that are available in New Zealand, including capsules, tablets, and powder, were used to prepare 2-mg/mL suspensions in 8.4% w/v sodium bicarbonate solution. The suspensions were then assessed visually for quality and by quantifying sedimentation rate over 120 minutes. Two products, stored in amber bottles at either 4°C or 25°C, demonstrated acceptable quality over a 30-day period whilst monitoring physical and chemical stability on day 0, 7, 14, 20, and 30. Four of the formulated suspensions were deemed to be of poor quality due to either a lack of uniformity or rapid sedimentation, attributes that could lead to inaccurate dosing. Acceptable quality suspensions were prepared from Losec and Dr. Reddy’s brands of omeprazole 20-mg capsules. For both brands, a change in color was observed after 20 days and 7 days when stored at 4°C and 25°C, respectively. Chemical stability was determined using a stability-indicating high-performance liquid chromatographic method, with >90% of the active remaining for 30 days when kept at 4°C, and 20 days when stored at 25°C. Not all brands are suitable for extemporaneously compounding omeprazole suspensions. Losec and Dr. Reddy’s brands of capsules were suitable to prepare quality omeprazole suspensions. Omeprazole suspensions compounded from these products are stable for 20 days if stored at 4°C and protected from light.

Related Keywords: Svenja Meissner, BPharm, Mahima Bansal, BPharm, MHSc, Paula Donamae Dela Cruz, BPharm, Sara Hanning, BPharm, PhD, Darren Svirskis, BHB, BPharm, PhD, New Zealand, omeprazole, proton pump inhibitor, gastroesophageal reflux disease, GERD, gastric ulcer, liquid suspensions, solid dosage forms, proprietary formulations, physical stability, chemical stability

Related Categories: GASTROENTEROLOGY, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS, STORAGE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment
Meissner Svenja
, Bansal Mahima, Dela Cruz Paula Donamae, Hanning Sara, Svirskis Darren
Mar/Apr 2020
Pg. 140-147

The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions
Svirskis Darren
, Lin Shao-Wei, Brown Helen, Sangaroomthong Annie, Shin Daniel, Wang Ziqi, Xu Hongtao, Dean Rebecca, Vareed Preetika, Jensen Maree, Wu Zimei
Mar/Apr 2018
Pg. 164-171

Chemical Stability of Extemporaneously Compounded Omeprazole Formulations: A Comparison of Two Methods of Compounding
Garg Sanjay
, Svirskis Darren, Al-Kabban Majid, Farhan Samer, Komeshi Mohammed, Lee Jacky, Liu Quincy, Naidoo Sacha, Kairuz Therese
May/Jun 2009
Pg. 250-253

Investigation of Filler Effects on the Compounding of Freeze-dried Orodispersible Tablets Containing Annona muricata Extract
Azman Syahiera Ezzah Noor
, Abd Razak Fashli Syafiq, Kamal Wan Hamirul Bahrin Wan, Zheng Gan Kok, Ming Long Chiau, Uddin ABM Helal, Sarker Zaidul Islam, Bin Liew Kai
Nov/Dec 2020
Pg. 509-514

Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma
Teeranachaideekul Veerawat
, Boonsongsawat Worrawee, Asanawittaya Waralee, Jintapattanakit Anchalee, Chantasart Doungdaw, Wongrakpanich Amaraporn
Jan/Feb 2021
Pg. 62-72

Alcohol-free Extemporaneous Formulations of Furosemide Are Chemically and Physically Stable in Ora-Blend Products for 30 Days
Svirskis Darren
, Jaffer Johaina, Agarwal Priyanka, Khan Ayeshah, Kaur Jaskarn, Cheng Alan, Hanning Sara
May/Jun 2020
Pg. 246-251

Setting Up a National System of Compounding Pharmacies: Preventing Error, Assuring Quality, Building Trust
Guedes de Souza Hugo
, Favaro Alvaro Jr, Andrade Alba Livia, Gomes Lenir Yago, de Souza Aguiar Simone, do Carmo Garcez Maria
Nov/Dec 2009
Pg. 532-536

PostScription: Setting up a National System of Compounding Pharmacies: An Introduction
Guedes de Souza Hugo
, Favaro Alvaro Jr, Andrade Alba Livia, Gomes Lenir Yago, de Souza Aguiar Simone, do Carmo Garcez Maria
Sep/Oct 2009
Pg. 447

Stability of Alprazolam, Atropine Sulfate, Glutamine, Levofloxacin, Metoprolol Tartrate, Nitrofurantoin, Ondansetron Hydrochloride, Oxandrolone, Pregabaline, and Riboflavin in SyrSpend SF pH4 Oral Suspensions
de Oliveira Ferreira Anderson
, Polonini Hudson C, Loures da Silva Sharlene, Cerqueira de Melo Victor Augusto, de Andrade Laura, Fernandes Brandão Marcos Antônio
May/Jun 2017
Pg. 255-263

Compounded Orodispersible Films with Natural Ingredients for Halitosis: A Clinical Experience
Apolinário Régis De Souza
, Chaves Maria Das Graças Afonso Miranda, Gonçalves Hanny Reis Mockdeci, Martins Isadora Conde Ferreria, De Paula Renée Mazilão, Granato Ana Paula Alves, Polonini Hudson Caetano, Brandão Marcos Antônio Fernandes, Ferreira Anderson De Oliveira, Raposo Nádia Rezende Barbosa
Nov/Dec 2018
Pg. 512-515

Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4
de Oliveira Ferreira Anderson
, Polonini Hudson, Loures da Silva Sharlene, Buzinari Aglio Natália Cristina, Abreu Jordana, Fernandes Brandão Marcos Antônio
Jul/Aug 2017
Pg. 339-346

Brazilian National System for the Monitoring and Improvement of Compounding Practices: Program Outcomes
Guedes de Souza Hugo
, Favaro Alvaro Jr, Andrade Alba Livia, Gomes Lenir Yago, do Carmo Garcez Maria
Mar/Apr 2012
Pg. 98-102

Development of a Novel Co-processed Excipitient Comprising of Xylitol, Mannitol, Microcrystalline Cellulose, and Crospovidone for the Compounding of Memantine Hydrochloride Orally Disintegrating Tablet
Hazdi Siti Nursaqifah
, Phang Hiu Ching, Ng Zhi Qi, Chew Yik Ling, Uddin ABM Helal, Sarker Zaidul Islam, Lee Siew-Keah, Liew Kai Bin
Nov/Dec 2023
Pg. 522-527

Orodispersible Films for Compounding Pharmacies
Ferreira Anderson O
, Brandão Marcos Antônio F, Raposo Francisco José, Polonini Hudson C, Raposo Nádia Rezende Barbosa
Nov/Dec 2017
Pg. 454-461

Comparison of Disintegrant-addition Methods on the Compounding of Orodispersible Tablets
Mahesparan Vishnu A/L
, Bin Abd Razak Fashli Syafiq, Ming Long Chiau, Uddin ABM Helal, Sarker Md Zaidul Islam, Bin Liew Kai
Mar/Apr 2020
Pg. 148-155

Pattern of Extemporaneous Prescriptions and Preparations in a Tertiary Health Institution: A Five-year Assessment
Aghahowa S E
, Egharevba J O, Erhagbe B E, Okoh F
Sep/Oct 2013
Pg. 432-435

Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson
, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
Nov/Dec 2018
Pg. 516-526

Compounding and Characterization of Oral Disintegrating Films Containing Memantine Hydrochloride for Geriatrics
Rofiq Hanifah Mohd
, Phang Hiu Ching, Janakiraman Ashok Kumar, Chew Yik-Ling, Uddin ABM Helal, Sarker Zaidul Islam, Lee Siew-Keah, Liew Kai Bin
Nov/Dec 2023
Pg. 512-521

Investigation of the Effects of Excipients in the Compounding of Amlodipine Besylate Orally Disintegrating Tablets
Azmi Nurual Hanisah Saiful
, Ming Long Chiau, Uddin A.B.M. Helal, Sarker Zaidul Islam, Bin Liew Kai
Jan/Feb 2022
Pg. 80-87

Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions
Polonini HC
, Loures S, Lima LC, Ferreira AO, Brandão MA
Mar/Apr 2016
Pg. 167-174

Return to Top